Clinical trial NCT02803515: Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : Predictive Marker and Mechanism
Official title: HSP90 as a Predictive Marker of the Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis From Ovarian Origin.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Peritoneal Carcinomatosis
Keywords: intra peritonal chemo hyperthermia
peritoneal carcinomatosis
ovarian cancer
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2016-06-17
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Peritoneal carcinomatosis (PC) is the stage III of the FIGO ovarian cancer staging. It corresponds to an advanced stage with a relative 5 year survival rate of 52%. The multimodal treatment approach combines neoadjuvant chemotherapy, cytoreductive surgery of macroscopic lesions, and hyperthermic intraperitoneal chemotherapy (HIPEC). It has significantly improved survival rate in patients with ovarian PC and decreased recurrence and mortality rate by 21%. The efficacy of HIPEC is based on chemotherapy potentiated by the hyperthermia (43°). However, the cellular mechanisms involved are not fully understood, but they include cell death pathways and heat shock proteins (Hsp70 and Hsp90). RICCI et al. showed, based on pre-clinical models, that the efficacy of HIPEC was partly due to the overexpression and exposure of HSP90 on the cell surface leaded to an anti-cancer immune response. The aims of this study are to validate these findings in tissue samples of patients with ovarian PC. We will constitute a bank of isolated tumor samples before and after HIPEC and measure postoperative HSP90 serum levels in order to establish if they are predictive of a response. HSPs expression on the cancer cell surface will be determined by flow cytometry. Forty-four patients will be included. Elucidating the underlying mechanisms of HIPEC will broaden therapeutic possibilities including the use of new immunotherapy. The multimodal approach could improve the efficacy of HIPEC with a minimal systemic toxicity.


Eligibility criteria: Inclusion Criteria:

* Females over 18 years.
* Indication of Hyperthermic Intra Peritoneal Chemotherapy (HIPEC) for peritoneal carcinomatosis from ovarian origin
* Obtaining written informed consent and signed for participation in the study and conservation of samples taken.
* Affiliation to a social security scheme.

Non-inclusion criteria

* Major patients protected by law or deprived of liberty.
* Patients pregnant women in labor or breastfeeding.
* Refusal of participation
* Another cause of peritoneal carcinomatosis

Exclusion Criteria:

* consent withdrawn

Primary outcomes:
measure: Changes in serum levels of HSP90 and 70 on peripheral venous samples.
timeFrame: basal levels (preoperatively), postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: Digestive department - Archet hospital
Study officials:
affiliation: Centre Hospitalier Universitaire de Nice
name: Jean-Marc BEREDER, MD
role: PRINCIPAL_INVESTIGATOR
References: